Literature DB >> 31158105

Somatic and germline sequencing in genitourinary oncology: genetics for the clinician.

Jonathan E Shoag1, David R Wise2, Ravi N Sharaf3, Cora N Sternberg4.   

Abstract

PURPOSE OF REVIEW: Next-generation sequencing is becoming more accessible. This review focuses on the clinical application of somatic and germline sequencing to genitourinary oncology. RECENT
FINDINGS: Germline variants have been increasingly recognized as contributing to the development of genitourinary malignancies, particularly in patients with advanced disease. A variety of commercial and institutional technologies are in use to detect variants, with newer tools focused on integrating these results into the clinical workflow.
SUMMARY: DNA sequencing is becoming a valuable tool in caring for patients with genitourinary malignancies. Performing both somatic and germline sequencing will likely become standard practice. Interpretation and clinical application of these results can be challenging and often requires multidisciplinary expertise.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31158105      PMCID: PMC9467627          DOI: 10.1097/MOU.0000000000000643

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.808


  12 in total

Review 1.  The emerging significance of secondary germline testing in cancer genomics.

Authors:  Diana Mandelker; Liying Zhang
Journal:  J Pathol       Date:  2018-02-16       Impact factor: 7.996

2.  Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.

Authors:  Diana Mandelker; Liying Zhang; Yelena Kemel; Zsofia K Stadler; Vijai Joseph; Ahmet Zehir; Nisha Pradhan; Angela Arnold; Michael F Walsh; Yirong Li; Anoop R Balakrishnan; Aijazuddin Syed; Meera Prasad; Khedoudja Nafa; Maria I Carlo; Karen A Cadoo; Meg Sheehan; Megan H Fleischut; Erin Salo-Mullen; Magan Trottier; Steven M Lipkin; Anne Lincoln; Semanti Mukherjee; Vignesh Ravichandran; Roy Cambria; Jesse Galle; Wassim Abida; Marcia E Arcila; Ryma Benayed; Ronak Shah; Kenneth Yu; Dean F Bajorin; Jonathan A Coleman; Steven D Leach; Maeve A Lowery; Julio Garcia-Aguilar; Philip W Kantoff; Charles L Sawyers; Maura N Dickler; Leonard Saltz; Robert J Motzer; Eileen M O'Reilly; Howard I Scher; Jose Baselga; David S Klimstra; David B Solit; David M Hyman; Michael F Berger; Marc Ladanyi; Mark E Robson; Kenneth Offit
Journal:  JAMA       Date:  2017-09-05       Impact factor: 56.272

3.  Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma.

Authors:  Maria I Carlo; Semanti Mukherjee; Diana Mandelker; Joseph Vijai; Yelena Kemel; Liying Zhang; Andrea Knezevic; Sujata Patil; Ozge Ceyhan-Birsoy; Kuo-Cheng Huang; Almedina Redzematovic; Devyn T Coskey; Carolyn Stewart; Nisha Pradhan; Angela G Arnold; A Ari Hakimi; Ying-Bei Chen; Jonathan A Coleman; David M Hyman; Marc Ladanyi; Karen A Cadoo; Michael F Walsh; Zsofia K Stadler; Chung-Han Lee; Darren R Feldman; Martin H Voss; Mark Robson; Robert J Motzer; Kenneth Offit
Journal:  JAMA Oncol       Date:  2018-09-01       Impact factor: 31.777

Review 4.  Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.

Authors:  Marilyn M Li; Michael Datto; Eric J Duncavage; Shashikant Kulkarni; Neal I Lindeman; Somak Roy; Apostolia M Tsimberidou; Cindy L Vnencak-Jones; Daynna J Wolff; Anas Younes; Marina N Nikiforova
Journal:  J Mol Diagn       Date:  2017-01       Impact factor: 5.568

5.  Germline mutations in DNA repair genes are associated with bladder cancer risk and unfavourable prognosis.

Authors:  Rong Na; Yishuo Wu; Guangliang Jiang; Hongjie Yu; Xiaoling Lin; Meilin Wang; Carly A Conran; Richard J Fantus; Ning Zhang; Shenghua Liu; Brian T Helfand; Siqun L Zheng; William B Isaacs; Qiang Ding; Zhoujun Shen; Jianfeng Xu
Journal:  BJU Int       Date:  2018-06-04       Impact factor: 5.588

Review 6.  Cancer genes associated with phenotypes in monoallelic and biallelic mutation carriers: new lessons from old players.

Authors:  Nazneen Rahman; Richard H Scott
Journal:  Hum Mol Genet       Date:  2007-04-15       Impact factor: 6.150

7.  Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management.

Authors:  Brian Shuch; Srinivas Vourganti; Christopher J Ricketts; Lindsay Middleton; James Peterson; Maria J Merino; Adam R Metwalli; Ramaprasad Srinivasan; W Marston Linehan
Journal:  J Clin Oncol       Date:  2013-12-30       Impact factor: 44.544

8.  Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines.

Authors:  Piper Nicolosi; Elisa Ledet; Shan Yang; Scott Michalski; Brandy Freschi; Erin O'Leary; Edward D Esplin; Robert L Nussbaum; Oliver Sartor
Journal:  JAMA Oncol       Date:  2019-04-01       Impact factor: 31.777

Review 9.  Realizing the promise of cancer predisposition genes.

Authors:  Nazneen Rahman
Journal:  Nature       Date:  2014-01-16       Impact factor: 49.962

10.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.

Authors:  Colin C Pritchard; Joaquin Mateo; Michael F Walsh; Navonil De Sarkar; Wassim Abida; Himisha Beltran; Andrea Garofalo; Roman Gulati; Suzanne Carreira; Rosalind Eeles; Olivier Elemento; Mark A Rubin; Dan Robinson; Robert Lonigro; Maha Hussain; Arul Chinnaiyan; Jake Vinson; Julie Filipenko; Levi Garraway; Mary-Ellen Taplin; Saud AlDubayan; G Celine Han; Mallory Beightol; Colm Morrissey; Belinda Nghiem; Heather H Cheng; Bruce Montgomery; Tom Walsh; Silvia Casadei; Michael Berger; Liying Zhang; Ahmet Zehir; Joseph Vijai; Howard I Scher; Charles Sawyers; Nikolaus Schultz; Philip W Kantoff; David Solit; Mark Robson; Eliezer M Van Allen; Kenneth Offit; Johann de Bono; Peter S Nelson
Journal:  N Engl J Med       Date:  2016-07-06       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.